The European Commission approved Vabysmo for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion, according to a press release from Roche.
“Vabysmo is the first bispecific antibody approved for RVO and the first new treatment for people with RVO in the European Union since 2015,” a Roche spokesperson told Healio. “By potentially extending the time between treatments to up to 4 months while maintaining vision, Vabysmo could offer a less burdensome treatment schedule for people living with RVO, their caregivers and health care systems.”